Clinical research - Today Stories

Survey points to importance of strategic engagement with investors and effective asset development strategies to optimise funding Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding. A recent survey of over 130 biotech executives, published by ICON, shows that 60% of respondents expected to increase R&D spending, whilst only 2% planned to reduce funding. While respondents were confident in their outlook with regards to investment milestones and product su…

Healthcare intelligence organisation earns recognition as employer of choice and leading innovator in the clinical trial industry Dublin, Ireland – 18 December 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation (CRO), finishes the second half of 2023 with positive recognition as a top-rated employer and leader in clinical trial innovation.  In recognition of its Environmental, Social and Governance (ESG) efforts and as an employer of choice, ICON ranked 88th in TIME’s list of the World’s Best Companies of 2023, the highest ranking CRO within the top 750 companies included. The award evaluates companies using standardised KPIs on sustainability, revenue and employee satisfaction. ICON was also included on both the Forbes World’s Best E…

Almac Discovery and Queen’s University Belfast have today announced a five-year project to develop a new Chemoproteomics Centre of Excellence for drug discovery.The multi-million-pound facility, which is jointly funded by Almac Discovery and a BBSRC Prosperity Partnership award, is a first of its kind in Northern Ireland and will be located at Queen’s.The project combines and harnesses the experience of industrial and academic experts to shine a new light on the way drug molecules could be used to treat disease, by using advanced mass spectrometry techniques to examine their effects on thousands of potential drug targets simultaneously, in disease relevant systems.This latest collaboration builds on a long-established relationship between Almac Discovery and Queen’s in biological research…

Prestigious industry recognition reflects company’s commitment to the development of strong site relationships in support of patients DURHAM, N.C., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been awarded the 2023 Society for Clinical Research Sites (SCRS) Eagle Award (CRO category). Parexel received the award at the annual Global Site Solutions Summit held Oct. 6-8 in Hollywood, Fla. The SCRS Eagle Award recognizes the sponsor and CRO committed to outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships. “Parexel’s collaboration with s…

Solution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards Dublin, Ireland – 20 September 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to…

WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, today announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC). The collaboration supports biopharmaceutical and biotech customers in meeting regulatory expectations to enroll and retain patients in clinical trials who more fully reflect real-world populations experiencing the disease or health condition being studied, including U.S. Food and Drug Administration requirements around diversity action plans. The work reflects Thermo Fisher and NMQF’s share…

Caidya was honored at the CRO Leadership Awards held in Boston, MA at the end of June for their win in the Overall Capabilities category. The award is a recognition of Caidya’s outstanding global capabilities and the tireless work that the team does daily to fulfill our vision to ensure potential therapies have the best opportunity to reach patients in need. Vice President of Business Development (China), Jinye Shen, attended on behalf of Caidya and expressed her gratitude and excitement for the award in a brief interview with the hosting president, Krishnan Rajugopalan. Key points she raised are: Caidya operates with an ownership mentality towards clinical research, making our clients’ success a measure of our own success. As a global company, we help clients navigate regulatory complexi…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…

Chicago, IL (May 25, 2023) — Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a biopharmaceutical industry-first collaboration with StuffThatWorks, the first data-driven community platform that uses crowdsourcing and AI to transform patient journeys and health metrics into actionable real world data in an effort to streamline research and bring clinical research closer to patients and caregivers. StuffThatWorks is home to 3M members world-wide who share their medical history and update on key condition and treatment parameters on an ongoing basis, in standard form across 750 conditions. Data shared by patients now amounts to 1.3M structured data points…

Company receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been rated the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated. “Study start-up has significantly increased in complexity and the pressure on investigative sites has never…

Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies. Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach. The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development.  CARY, N.C., May 23, 2023 – Global b…

Tomorrow is #ClinicalTrialsDay 2023, a day dedicated to shining a spotlight on the clinical research community. Organised and promoted by ACRP since 2014, the day is celebrated on May 20th to recognise the day that James Lind started what is considered the first randomised clinical trial on May 20th, 1774. The day presents an opportunity for the community to pause in reflection, recognition, and admiration of all that has been accomplished thanks to clinical trials and the talented professionals driving them. Find out more about how you can get involved in #CTD2023: https://www.clinicaltrialsday.org/getinvolved

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology CRO – has announced the next phase in its ongoing growth plan with the opening of a brand-new 2,819 sq ft laboratory and office suite at Alderley Park. The newly established suite will accommodate the activities of the Big Blue® transgenic rodent mutation workflow, increasing capacity in this in-demand mutagenesis toxicology test and growing the Gentronix footprint at Alderley Park by 30%. This continued growth follows a successful 2300 sq ft. expansion in 2021 to increase capacity of genetic, ocular, and skin toxicology testing in 2021. Gentronix completed the acquisition of the Big Blue® transgenic rodent mutation assays in June 2021 and have subsequently undertaken an extensive proficiency exercise…

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers. Under the new framework, clinical trials application processes in UK will be more proportionate, streamlined and flexible without compromising on safety, helping to cement the UK as an attractive destination for trials, including global “multi-site” trials. For example, the integration of the regulatory and ethics reviews of clinical trial applications, w…

BALLERUP, DENMARK and DUBLIN, IRELAND — 10 March, 2023 — LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry. The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. It also represents LEO Pharma and ICON’s share…

Seeks to accelerate patient access to safe, effective, cutting-edge medical devices to diagnose and treat nervous systems disorders WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded a five-year contract to provide regulatory affairs support and related services for the Blueprint MedTech (BPMT) program, a new multi-institute/center initiative at the National Institutes of Health (NIH) supporting development of translational neurological devices. The BPMT program is a new NIH incubator with a collaborative reach across 11 NIH institutes, whose goal is to accelerate patient access to safe, effective, cutting-edge medical devices to diagnose and/or treat disorders of the nervous system.…

HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs). Clinical phase 1/2 study (LAPiS Study) will enrol 10 patients with advanced heart failure caused by ischaemic heart disease. Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood…

Study published today in Clinical Trials: Journal of the Society for Clinical Trials examined clinical trial diversity across 495 GSK trials involving over 100,000 participants Results demonstrate real-world disease epidemiology data—compared to the conventional standard of US Census data—may be better benchmark to ensure clinical trial enrolment reflects the populations affected by diseases GSK commits to applying insights from the study and collaborating with regulators, patients, academics and other biopharma companies to make meaningful progress on clinical trial diversity GSK plc (LSE/NYSE: GSK) today announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in GSK clinical trials. The study looked…

New collaboration leverages MyEyeDr.’s 850+ offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are BOSTON and DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced a formal agreement with MyEyeDr., a leading vision healthcare organization, to refer its patients into existing and future ophthalmology clinical trials. Parexel and MyEyeDr. are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinolog…

Milton Keynes, UK. (6 December 2022) – Medical Research Network, a leading Clinical Trial Organization, was presented with the Queen’s Award for Enterprise, International Trade at a company meeting last night. The award, established by Her Majesty Queen Elizabeth in 1965, celebrates the country’s most exciting and innovative companies, and is Britain’s most prestigious business award. The International Trade category is awarded to companies who have achieved spectacular growth and commercial success overseas. The presentation took place at a company-wide meeting held at the Wyboston Lakes Resort, near the MRN headquarters in Milton Keynes. MRN executives from France, Germany, Spain, and Japan were there to watch the presentation in person, while executives from the MRN office in Chicago wa…